DD101 Basic Drug Discovery and Development

This short course will give you the high-level description and performance stats for drug discovery and development. You will all learn about the various strategies used to solve this puzzle. And lastly you will be able to understand why organizations terminate projects.


accelerated approval, active pharmaceutical ingredient (API), anti-sense oligonucleotides (ASO), assay, biologics, biologics licensing application (BLA), biosimilar, breakthrough designation, clinical trial, Clinical trial application (CTA), Drug, drug candidates, drug discovery and development, gene therapy, generic, investigational new drug application (IND), irreversal morbidity, label, market authorization application (MAA), medicine, multiple ascending dose study (MAD), new drug application (NDA), Patient Recorded Outcomes (PRO), priority review, priority review voucher, proof of concept (POC), protein structure, Serious Adverse Events (SAE), Single Ascending Dose Study (SAD), surrogate

If you’re already an Atlas member login to start this course.

Not a member? Join now for full access to the Atlas.

Not ready to subscribe to the Atlas for access to unlimited courses?

Buy this course